New breakthrough in the field of biomedicine: gas-phase white carbon black drug delivery system enters clinical stage
Hits: 976
img
On July 5, 2025, Shanghai Ruijin Hospital announced that its gas-phase white carbon black based anti-cancer drug delivery system has completed phase I clinical trials. The system loads paclitaxel onto the surface of mesoporous silica (pore size 8nm) and achieves targeted enrichment of tumor tissue through EPR effect. The test data showed that in patients with advanced breast cancer, the maximum tolerable dose of the drug was increased to 210 mg/m ² (175 mg/m ² for traditional preparations), and the incidence of neurotoxicity decreased from 32% to 9%. At present, this technology has been recognized as a breakthrough therapy by the National Medical Products Administration, and it is expected to start phase III clinical trials in 2026.
